Brussels deregulated gene-edited crops on 17 June 2026, citing climate adaptation, food security, and EU competitiveness. NGT-1 crops under 20 genetic modifications now skip risk assessment and traceability. But while labeling rules were dropped, patent rights for Bayer, Syngenta, and Corteva stayed untouched. This piece breaks down the real governance failure behind the CRISPR crop vote.

Every ESG framework measures board composition and audit independence. Almost none ask the question that determines whether governance actually works: who decides which harms are worth measuring? That is not abstract. It has a documented history. In CSR, we call it materiality assessment. The mechanism sounds technical. It is not. It is a values decision dressed in accounting language. And when you trace it back through history, the pattern is impossible to ignore.

We spent two years as an external consultant watching companies hire managers and directors. They paid us to improve their processes. What we saw was a masterclass in how bias disguises itself as professional judgment. Same credentials on paper. Wildly different outcomes in practice. Here’s what nobody wants to admit.

Climate change isn’t just melting ice caps—it’s raising women’s cancer risks. A new study links every 1°C rise in temperature to higher rates of breast, ovarian, uterine, and cervical cancers. As a CSR strategist, I argue this isn’t just a health issue—it’s a justice issue. Climate, gender, and health are colliding, and women are paying the price. It’s time to treat climate action as women’s health policy, and women’s health as climate strategy.

Discover the century-long journey to gender equality in the Olympics, culminating in the historic 2024 Paris Games.